Wedbush Has Positive Estimate for STOK FY2024 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Wedbush upped their FY2024 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a research note issued on Tuesday, November 5th. Wedbush analyst L. Chico now expects that the company will post earnings per share of ($2.00) for the year, up from their previous forecast of ($2.03). The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.10) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q3 2025 earnings at ($0.62) EPS, FY2025 earnings at ($2.40) EPS, FY2026 earnings at ($2.51) EPS, FY2027 earnings at ($2.05) EPS and FY2028 earnings at ($0.76) EPS.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. The company had revenue of $4.89 million during the quarter, compared to the consensus estimate of $3.46 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%.

STOK has been the subject of several other research reports. Leerink Partners started coverage on shares of Stoke Therapeutics in a report on Monday, October 14th. They set an “outperform” rating and a $18.00 target price for the company. HC Wainwright restated a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a report on Wednesday. Needham & Company LLC reiterated a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research note on Wednesday. Finally, Leerink Partnrs raised Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Stoke Therapeutics presently has an average rating of “Buy” and an average target price of $20.83.

Stoke Therapeutics Stock Up 4.6 %

STOK opened at $13.88 on Friday. Stoke Therapeutics has a 12-month low of $3.77 and a 12-month high of $17.58. The business has a 50 day moving average of $13.21 and a 200-day moving average of $13.72. The stock has a market cap of $735.22 million, a price-to-earnings ratio of -6.61 and a beta of 0.95.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in STOK. Quest Partners LLC bought a new position in Stoke Therapeutics during the 2nd quarter worth $29,000. Nisa Investment Advisors LLC raised its holdings in shares of Stoke Therapeutics by 53.2% in the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock valued at $40,000 after purchasing an additional 1,038 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Stoke Therapeutics during the second quarter valued at about $123,000. State Board of Administration of Florida Retirement System purchased a new position in Stoke Therapeutics during the first quarter worth about $141,000. Finally, Intech Investment Management LLC bought a new stake in Stoke Therapeutics in the 3rd quarter worth about $160,000.

Insiders Place Their Bets

In related news, major shareholder Skorpios Trust sold 1,937,500 shares of the stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $14.05, for a total value of $27,221,875.00. Following the completion of the transaction, the insider now owns 8,906,181 shares of the company’s stock, valued at $125,131,843.05. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 11.30% of the company’s stock.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.